Literature DB >> 10329727

sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1.

P Pagès1, N Benali, N Saint-Laurent, J P Estève, A V Schally, J Tkaczuk, N Vaysse, C Susini, L Buscail.   

Abstract

Activation of the somatostatin receptor sst2 inhibits cell proliferation by a mechanism involving the stimulation of the protein-tyrosine phosphatase SHP-1. The cell cycle regulatory events leading to sst2-mediated growth arrest are not known. Here, we report that treatment of Chinese hamster ovary cells expressing sst2 with the somatostatin analogue, RC-160, led to G1 cell cycle arrest and inhibition of insulin-induced S-phase entry through induction of the cyclin-dependent kinase inhibitor p27(Kip1). Consequently, a decrease of p27(Kip1)-cdk2 association, an inhibition of insulin-induced cyclin E-cdk2 kinase activity, and an accumulation of hypophosphorylated retinoblastoma gene product (Rb) were observed. However, RC-160 had no effect on the p21(Waf1/Cip1). When sst2 was coexpressed with a catalytically inactive mutant SHP-1 in Chinese hamster ovary cells, mutant SHP-1 induced entry into cell cycle and down-regulation of p27(Kip1) and prevented modulation by insulin and RC-160 of p27(Kip1) expression, p27(Kip1)-cdk2 association, cyclin E-cdk2 kinase activity, and the phosphorylation state of Rb. In mouse pancreatic acini, RC-160 reverted down-regulation of p27(Kip1) induced by a mitogen, and this effect did not occur in acini from viable motheaten (mev/mev) mice expressing a mutant SHP-1 with markedly deficient enzymes. These findings provide the first evidence that sst2 induces cell cycle arrest through the up-regulation of p27(Kip1) and demonstrate that SHP-1 is required for maintaining high inhibitory levels of p27(Kip1) and is a critical target of the insulin, and somatostatin signaling cascade, leading to the modulation of p27(Kip1).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329727     DOI: 10.1074/jbc.274.21.15186

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Growth inhibition by the muscarinic M(3) acetylcholine receptor: evidence for p21(Cip1/Waf1) involvement in G(1) arrest.

Authors:  Drew Burdon; Rajnikant Patel; R A John Challiss; Jonathan L Blank
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

2.  An enteroendocrine cell-based model for a quiescent intestinal stem cell niche.

Authors:  I R Radford; P N Lobachevsky
Journal:  Cell Prolif       Date:  2006-10       Impact factor: 6.831

3.  Correlation between the expressions of gastrin, somatostatin and cyclin and cyclin-depend kinase in colorectal cancer.

Authors:  Pei Wu; Jia-Ding Mao; Jing-Yi Yan; Jing Rui; You-Cai Zhao; Xian-Hai Li; Guo-Qiang Xu
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

4.  Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Authors:  Geraldine Ferjoux; Frederic Lopez; Jean-Pierre Esteve; Audrey Ferrand; Eric Vivier; Frederic Vely; Nathalie Saint-Laurent; Lucien Pradayrol; Louis Buscail; Christiane Susini
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

5.  Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells.

Authors:  B Mariniello; I Finco; P Sartorato; A Patalano; M Iacobone; V Guzzardo; A Fassina; F Mantero
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

Review 6.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

7.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

8.  Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.

Authors:  N Benali; P Cordelier; D Calise; P Pages; P Rochaix; A Nagy; J P Esteve; P M Pour; A V Schally; N Vaysse; C Susini; L Buscail
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

9.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

10.  Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.

Authors:  C G Ziegler; J W Brown; A V Schally; A Erler; L Gebauer; A Treszl; L Young; L M Fishman; J B Engel; H S Willenberg; S Petersenn; G Eisenhofer; M Ehrhart-Bornstein; S R Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.